CLGN — Collplant Biotechnologies Income Statement
0.000.00%
Last trade - 00:00
- $67.47m
- $40.79m
- $10.96m
- 53
- 22
- 76
- 49
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.32 | 6.14 | 15.6 | 0.299 | 11 |
Cost of Revenue | |||||
Gross Profit | 0.439 | 3.13 | 14 | 0.195 | 9.83 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.95 | 11.7 | 15.6 | 17.4 | 18.5 |
Operating Profit | -7.63 | -5.6 | 0.065 | -17.1 | -7.51 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.2 | -5.77 | 0.237 | -16.9 | -7.02 |
Net Income After Taxes | -11.2 | -5.77 | 0.237 | -16.9 | -7.02 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.2 | -5.77 | 0.237 | -16.9 | -7.02 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.2 | -5.77 | 0.237 | -16.9 | -7.02 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.24 | -0.838 | 0.053 | -1.51 | -0.533 |